OMY Stock Overview
Synairgen plc discovers and develops drugs for respiratory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Synairgen plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.023 |
| 52 Week High | UK£0.098 |
| 52 Week Low | UK£0.006 |
| Beta | -2.37 |
| 11 Month Change | -43.21% |
| 3 Month Change | 91.67% |
| 1 Year Change | -71.81% |
| 33 Year Change | -99.04% |
| 5 Year Change | n/a |
| Change since IPO | -98.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| OMY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 12.2% | -0.2% | 0.8% |
| 1Y | -71.8% | -16.9% | 9.1% |
Return vs Industry: OMY underperformed the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: OMY underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| OMY volatility | |
|---|---|
| OMY Average Weekly Movement | 140.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OMY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: OMY's weekly volatility has increased from 79% to 140% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 36 | Richard Marsden | www.synairgen.com |
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Synairgen plc Fundamentals Summary
| OMY fundamental statistics | |
|---|---|
| Market cap | €11.51m |
| Earnings (TTM) | -€8.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs OMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMY income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£6.92m |
| Earnings | -UK£6.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OMY perform over the long term?
See historical performance and comparison